Biotech Values

[Titan V]

Here's a Biotech IPO You'll Want to Watch [Jounce Therapeutics; MRK, BMY, CELG]
http://www.fool.com/investing/2017/01/09/heres-a-biotech-ipo-youll-want-to-watch.aspx

Jounce has a grand total of one candidate in clinical testing -- experimental cancer drug JTX-2011. And it's only in early-stage development. JTX-2011 has enough potential, though, that Celgene paid the small biotech $225 million up front and bought a $36 million stake in the company. The deal also includes an option for Celgene to license up to four other immunotherapies.